Biolidics has received product authorisation from Indonesia’s ministry of health for the usage and distribution of the company’s ClearEpi SARS-CoV-2 Antigen Rapid Test Kit (ClearEpi ART) in Indonesia. 

In a filing to SGX dated March 15, the company states that the authorisation remains valid until March 10, 2022, and the extension of its validity may be permissible should there be no undesirable events upon usage.

Biolidics notes that antigen rapid test kits such as the ClearEpi ART are different from serology rapid test kits for the detection of Covid-19 antibodies. Serology tests are administered via blood draw and seek to detect antibodies that usually appear in patients during the recovery phase of Covid-19, whereas antigen tests are performed via nasal swab and detect viral proteins in patients during the acute phase of the virus.


To continue reading,

Sign in to access this Premium article.

Subscription entitlements:

Less than $9 per month
3 Simultaneous logins across all devices
Unlimited access to latest and premium articles
Bonus unlimited access to online articles and virtual newspaper on The Edge Malaysia (single login)

Stay updated with Singapore corporate news stories for FREE

Follow our Telegram | Facebook